Challenge
A Ukrainian technology institute wanted to commercialise a unique, non-invasive cardiac screening technology, a first level diagnostic tool for initial evaluation of patients at risk for cardiac disease or defects.
Approach
We helped their team of researchers secure IP rights, complete a market research and a feasibility study, and prepare a business plan. Our collaboration with Cadriomox help raise £2 million to start up. In 2020 the company is now preparing for CE marking in the UK and its Chinese partner is preparing for approval from the China Food and Drug Administration.
Impact
Our support played a key role in ensuring the startup remained statutorily compliant, despite its small size and limited resources. We helped the company stay on track with key deadlines, reducing penalty or disruption risks. Our ongoing guidance allowed them to focus on growth and operations while maintaining their financial and legal responsibilities.
